Biotech Values

[stuck_holder]

<Loewen, Ondaatje, McCutcheon analyst Nigel deGruyther said that because of the agreement, Tekmira now has a deal with Roche that could see it potentially reap milestone payments of $52 million from four products developed, with between $5 million to $15 million expected over the next few years. But deGruyther, who has a 12-month target of C$4.20 on the stock, said Tekmira's work with Hana Biosciences (HNAB) to develop Marqibo, an anti-cancer drug, was also adding "more legs" to the shares.>

interesting. i thought Hana had dropped Marquibo in March after discontinuing their previous SPA, but now see they are pusuring it for leukemia under a different protocol using randomized trials, as well as for non-hodgkins lymphoma.

thanks for posting that.